Rocket Pharmaceuticals Financials - Benzinga

Rocket Pharmaceuticals Inc

RCKTNASDAQ

Trade with Public

Trade with Public

$3.86

0.133.49%

At close: Sep 2, 5:00 PM EST

$3.84

-0.02-0.52%

After Hours: 6:19 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Rocket Pharmaceuticals Financials

Rocket Pharmaceuticals (RCKT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $0.24 by 254.17 percent. This is a 40.32 percent increase over losses of $(0.62) per

Benzinga Newsdesk

PRO
Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 25 percent increase over losses of $(0.56) per share

Benzinga Newsdesk

PRO
Rocket Pharmaceuticals Q4 EPS $(0.38) Beats $(0.44) Estimate

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.04 percent. This is a 38.71 percent increase over losses of $(0.62) per share

Benzinga Newsdesk

PRO
Rocket Pharmaceuticals Q3 EPS $(0.45) Beats $(0.52) Estimate

Benzinga Newsdesk

PRO
Rocket Pharmaceuticals Q2 EPS $(0.62) Misses $(0.56) Estimate

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.56) by 10.91 percent. This is a 16.22 percent increase over losses of $(0.74) per

Benzinga Newsdesk

Dow Surges Over 600 Points; US Durable Goods Orders Fall in April

Avi Kapoor